Related Experiment Video
Updated: Aug 15, 2026
Quantitative Analyses of all Influenza Type A Viral Hemagglutinins and Neuraminidases using Universal Antibodies in Simple Slot Blot Assays
Published on: April 4, 2011
Serological determination of hepatitis C virus subtypes 1a, 1b, 2a, 2b, 3a, and 4a by a recombinant immunoblot assay
M Schröter1, H H Feucht, P Schäfer
1Institut für Medizinische Mikrobiologie und Immunologie, Universitäts-Krankenhaus Eppendorf, 20246 Hamburg, Germany. mschroet@uke.uni-hamburg.de
Insights
A new recombinant immunoblot assay allows for serological differentiation of Hepatitis C virus (HCV) subtypes. This method accurately identifies HCV subtypes, offering a simpler tool for clinical and epidemiological studies.
Area of Science:
- Virology
- Immunology
- Molecular Biology
Background:
- Serological determination of Hepatitis C virus (HCV) subtypes is crucial for epidemiological tracking and treatment but has been limited by the absence of suitable diagnostic assays.
- Accurate identification of HCV subtypes is essential for understanding transmission patterns and optimizing patient management.
Purpose of the Study:
- To establish and validate a novel recombinant immunoblot assay for the serological differentiation of common Hepatitis C virus (HCV) subtypes.
- To compare the performance of the developed serotyping assay with established molecular methods like nucleotide sequencing.
Main Methods:
- Development of a recombinant immunoblot assay utilizing recombinant HCV proteins from the NS-4 region, expressed in Escherichia coli.
- Testing of sera from 157 patients with chronic HCV infection using the developed assay.
- Confirmation of serotyping results by comparing them with HCV subtype determination via nucleotide sequencing of the NS-5 region.
Main Results:
- The assay detected specific antibodies in 86% (n=135) of patients with chronic HCV infection.
- HCV genotype determination was accurate in all but one sample.
- The serotyping assay correctly identified HCV subtypes corresponding to nucleotide sequencing results in 95% (n=128) of samples.
Conclusions:
- Hepatitis C virus (HCV) subtypes can be reliably distinguished using serological methods.
- The developed recombinant immunoblot assay offers a simpler and effective means for identifying different HCV subtypes, facilitating broader clinical and epidemiological applications.
Abstract:
Serological determination of hepatitis C virus (HCV) subtypes has been hampered by the lack of suitable assays. Therefore, a recombinant immunoblot assay has been established for serological differentiation of HCV subtypes 1a, 1b, 2a, 2b, 3a, and 4a. It consists of recombinant HCV proteins from the NS-4 region propagated in Escherichia coli. To confirm the serotyping assay results, the results were compared with those obtained by nucleotide sequencing of the NS-5 region. Sera from 157 patients with chronic HCV infection were examined by this assay, and specific antibodies could be detected in 86% (n = 135) of them. The HCV genotype was determined correctly in all but one sample, and the subtypes determined by the serotyping assay corresponded to the HCV subtypes detected by nucleotide sequencing for 95% (n = 128) of the samples. These data indicate that HCV subtypes can be distinguished serologically. The assay that is described provides an easier means of identification of infection with different HCV subtypes for wider clinical and epidemiological applications.
